Template:Microscopic evaluation of neoadjuvant invasive cancer - Revision history

Mikael Häggström: Format

2023-11-13T17:52:34Z

Format

← Older revision		Revision as of 13:52, 13 November 2023
Line 2:		Line 2:
	\|author1=[[User:Mikael Häggström\|Mikael Häggström]]		\|author1=[[User:Mikael Häggström\|Mikael Häggström]]
	\|author2=		\|author2=
	}}</noinclude>{{Edit\|Template:Microscopic evaluation of neoadjuvant invasive cancer}}</br>If not already stated, look for clues that neoadjuvant treatment has been given, that is, when the patient has received chemotherapy, endocrine therapy and/or radiotherapy before the excision. Look more thoroughly for it if the duration between a previous biopsy and subsequent excision is longer than usual (usually about a month<ref name="pmid19437077">{{cite journal\| author=van Esser S, Peters NH, van den Bosch MA, Mali WP, Peeters PH, Borel Rinkes IH \| display-authors=etal\| title=Surgical outcome of patients with core-biopsy-proven nonpalpable breast carcinoma: a large cohort follow-up study. \| journal=Ann Surg Oncol \| year= 2009 \| volume= 16 \| issue= 8 \| pages= 2252-8 \| pmid=19437077 \| doi=10.1245/s10434-009-0513-6 \| pmc=2711911 \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19437077 }} </ref>).		}}</noinclude>{{Edit\|Template:Microscopic evaluation of neoadjuvant invasive cancer}}</br>If not already stated, look for clues that neoadjuvant treatment has been given, that is, when the patient has received chemotherapy, endocrine therapy and/or radiotherapy before the excision. Look more thoroughly for it if the duration between a previous biopsy and subsequent excision is longer than usual. It's usually about a month.<ref name="pmid19437077">{{cite journal\| author=van Esser S, Peters NH, van den Bosch MA, Mali WP, Peeters PH, Borel Rinkes IH \| display-authors=etal\| title=Surgical outcome of patients with core-biopsy-proven nonpalpable breast carcinoma: a large cohort follow-up study. \| journal=Ann Surg Oncol \| year= 2009 \| volume= 16 \| issue= 8 \| pages= 2252-8 \| pmid=19437077 \| doi=10.1245/s10434-009-0513-6 \| pmc=2711911 \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19437077 }} </ref>

	In neoadjuvant cases , perform:		In neoadjuvant cases , perform:

Mikael Häggström: Look for clues

2023-11-13T17:46:07Z

Look for clues

← Older revision		Revision as of 13:46, 13 November 2023
Line 2:		Line 2:
	\|author1=[[User:Mikael Häggström\|Mikael Häggström]]		\|author1=[[User:Mikael Häggström\|Mikael Häggström]]
	\|author2=		\|author2=
	}}</noinclude>{{Edit\|Template:Microscopic evaluation of neoadjuvant invasive cancer}}</br>In neoadjuvant ~~cases (~~patient has received chemotherapy, endocrine therapy and/or radiotherapy before the excision), perform:		}}</noinclude>{{Edit\|Template:Microscopic evaluation of neoadjuvant invasive cancer}}</br>If not already stated, look for clues that neoadjuvant treatment has been given, that is, when the patient has received chemotherapy, endocrine therapy and/or radiotherapy before the excision. Look more thoroughly for it if the duration between a previous biopsy and subsequent excision is longer than usual (usually about a month<ref name="pmid19437077">{{cite journal\| author=van Esser S, Peters NH, van den Bosch MA, Mali WP, Peeters PH, Borel Rinkes IH \| display-authors=etal\| title=Surgical outcome of patients with core-biopsy-proven nonpalpable breast carcinoma: a large cohort follow-up study. \| journal=Ann Surg Oncol \| year= 2009 \| volume= 16 \| issue= 8 \| pages= 2252-8 \| pmid=19437077 \| doi=10.1245/s10434-009-0513-6 \| pmc=2711911 \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19437077 }} </ref>).

			In neoadjuvant cases , perform:
	*Measurement of the '''tumor bed''' which generally manifests as a fibroelastic area.		*Measurement of the '''tumor bed''' which generally manifests as a fibroelastic area.
	*Classification of '''residual cancer''', for which there are multiple systems, mainly ''Residual Cancer Burden'' (RCB)<ref group=note>A calculator and explanations for calculating RCB is found at: http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3</ref> and the American Joint Committee on Cancer post-neoadjuvant therapy staging system (yAJCC).<ref name="pmid28577078">{{cite journal\| author=Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A \| display-authors=etal\| title=Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). \| journal=Breast Cancer Res Treat \| year= 2017 \| volume= 165 \| issue= 1 \| pages= 181-191 \| pmid=28577078 \| doi=10.1007/s10549-017-4303-8 \| pmc=5653207 \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28577078 }} </ref><noinclude>		*Classification of '''residual cancer''', for which there are multiple systems, mainly ''Residual Cancer Burden'' (RCB)<ref group=note>A calculator and explanations for calculating RCB is found at: http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3</ref> and the American Joint Committee on Cancer post-neoadjuvant therapy staging system (yAJCC).<ref name="pmid28577078">{{cite journal\| author=Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A \| display-authors=etal\| title=Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). \| journal=Breast Cancer Res Treat \| year= 2017 \| volume= 165 \| issue= 1 \| pages= 181-191 \| pmid=28577078 \| doi=10.1007/s10549-017-4303-8 \| pmc=5653207 \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28577078 }} </ref><noinclude>
	{{Bottom}}		{{Bottom}}
	</noinclude>		</noinclude>

Mikael Häggström: Note

2022-06-21T18:12:33Z

Note

← Older revision		Revision as of 14:12, 21 June 2022
Line 4:		Line 4:
	}}</noinclude>{{Edit\|Template:Microscopic evaluation of neoadjuvant invasive cancer}}</br>In neoadjuvant cases (patient has received chemotherapy, endocrine therapy and/or radiotherapy before the excision), perform:		}}</noinclude>{{Edit\|Template:Microscopic evaluation of neoadjuvant invasive cancer}}</br>In neoadjuvant cases (patient has received chemotherapy, endocrine therapy and/or radiotherapy before the excision), perform:
	*Measurement of the '''tumor bed''' which generally manifests as a fibroelastic area.		*Measurement of the '''tumor bed''' which generally manifests as a fibroelastic area.
	*Classification of '''residual cancer''', for which there are multiple systems, mainly ''Residual Cancer Burden'' (RCB)<ref group=~~notes~~>A calculator and explanations for calculating RCB is found at: http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3</ref> and the American Joint Committee on Cancer post-neoadjuvant therapy staging system (yAJCC).<ref name="pmid28577078">{{cite journal\| author=Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A \| display-authors=etal\| title=Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). \| journal=Breast Cancer Res Treat \| year= 2017 \| volume= 165 \| issue= 1 \| pages= 181-191 \| pmid=28577078 \| doi=10.1007/s10549-017-4303-8 \| pmc=5653207 \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28577078 }} </ref><noinclude>		*Classification of '''residual cancer''', for which there are multiple systems, mainly ''Residual Cancer Burden'' (RCB)<ref group=note>A calculator and explanations for calculating RCB is found at: http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3</ref> and the American Joint Committee on Cancer post-neoadjuvant therapy staging system (yAJCC).<ref name="pmid28577078">{{cite journal\| author=Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A \| display-authors=etal\| title=Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). \| journal=Breast Cancer Res Treat \| year= 2017 \| volume= 165 \| issue= 1 \| pages= 181-191 \| pmid=28577078 \| doi=10.1007/s10549-017-4303-8 \| pmc=5653207 \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28577078 }} </ref><noinclude>
	{{Bottom}}		{{Bottom}}
	</noinclude>		</noinclude>

Mikael Häggström: Format

2021-09-17T15:30:15Z

Format

← Older revision		Revision as of 11:30, 17 September 2021
Line 1:		Line 1:
	{{Top		<noinclude>{{Top
	\|author1=[[User:Mikael Häggström\|Mikael Häggström]]		\|author1=[[User:Mikael Häggström\|Mikael Häggström]]
	\|author2=		\|author2=
	}}<noinclude>		}}</noinclude>{{Edit\|Template:Microscopic evaluation of neoadjuvant invasive cancer}}</br>In neoadjuvant cases (patient has received chemotherapy, endocrine therapy and/or radiotherapy before the excision), perform:
	{{~~Bottom~~}}
	</~~noinclude~~>In neoadjuvant cases (patient has received chemotherapy, endocrine therapy and/or radiotherapy before the excision), perform:
	*Measurement of the '''tumor bed''' which generally manifests as a fibroelastic area.		*Measurement of the '''tumor bed''' which generally manifests as a fibroelastic area.
	*Classification of '''residual cancer''', for which there are multiple systems, mainly ''Residual Cancer Burden'' (RCB)<ref group=notes>A calculator and explanations for calculating RCB is found at: http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3</ref> and the American Joint Committee on Cancer post-neoadjuvant therapy staging system (yAJCC).<ref name="pmid28577078">{{cite journal\| author=Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A \| display-authors=etal\| title=Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). \| journal=Breast Cancer Res Treat \| year= 2017 \| volume= 165 \| issue= 1 \| pages= 181-191 \| pmid=28577078 \| doi=10.1007/s10549-017-4303-8 \| pmc=5653207 \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28577078 }} </ref><noinclude>		*Classification of '''residual cancer''', for which there are multiple systems, mainly ''Residual Cancer Burden'' (RCB)<ref group=notes>A calculator and explanations for calculating RCB is found at: http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3</ref> and the American Joint Committee on Cancer post-neoadjuvant therapy staging system (yAJCC).<ref name="pmid28577078">{{cite journal\| author=Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A \| display-authors=etal\| title=Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). \| journal=Breast Cancer Res Treat \| year= 2017 \| volume= 165 \| issue= 1 \| pages= 181-191 \| pmid=28577078 \| doi=10.1007/s10549-017-4303-8 \| pmc=5653207 \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28577078 }} </ref><noinclude>
	{{Bottom}}		{{Bottom}}
	</noinclude>		</noinclude>

Mikael Häggström: Wording

2021-09-17T15:22:46Z

Wording

← Older revision		Revision as of 11:22, 17 September 2021
Line 4:		Line 4:
	}}<noinclude>		}}<noinclude>
	{{Bottom}}		{{Bottom}}
	</noinclude>In neoadjuvant cases, ~~measure~~:		</noinclude>In neoadjuvant cases (patient has received chemotherapy, endocrine therapy and/or radiotherapy before the excision), perform:
	*'''~~Tumor~~ bed''' which generally manifests as a fibroelastic area.		*Measurement of the '''tumor bed''' which generally manifests as a fibroelastic area.
	*Classification of '''residual cancer''', for which there are multiple systems, mainly ''Residual Cancer Burden'' (RCB)<ref group=notes>A calculator and explanations for calculating RCB is found at: http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3</ref> and the American Joint Committee on Cancer post-neoadjuvant therapy staging system (yAJCC).<ref name="pmid28577078">{{cite journal\| author=Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A \| display-authors=etal\| title=Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). \| journal=Breast Cancer Res Treat \| year= 2017 \| volume= 165 \| issue= 1 \| pages= 181-191 \| pmid=28577078 \| doi=10.1007/s10549-017-4303-8 \| pmc=5653207 \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28577078 }} </ref><noinclude>		*Classification of '''residual cancer''', for which there are multiple systems, mainly ''Residual Cancer Burden'' (RCB)<ref group=notes>A calculator and explanations for calculating RCB is found at: http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3</ref> and the American Joint Committee on Cancer post-neoadjuvant therapy staging system (yAJCC).<ref name="pmid28577078">{{cite journal\| author=Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A \| display-authors=etal\| title=Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). \| journal=Breast Cancer Res Treat \| year= 2017 \| volume= 165 \| issue= 1 \| pages= 181-191 \| pmid=28577078 \| doi=10.1007/s10549-017-4303-8 \| pmc=5653207 \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28577078 }} </ref><noinclude>
	{{Bottom}}		{{Bottom}}
	</noinclude>		</noinclude>

Mikael Häggström: Noinclude

2021-09-17T15:19:17Z

Noinclude

← Older revision		Revision as of 11:19, 17 September 2021
Line 1:		Line 1:
	In neoadjuvant cases, measure:		{{Top
			\|author1=[[User:Mikael Häggström\|Mikael Häggström]]
			\|author2=
			}}<noinclude>
			{{Bottom}}
			</noinclude>In neoadjuvant cases, measure:
	*'''Tumor bed''' which generally manifests as a fibroelastic area.		*'''Tumor bed''' which generally manifests as a fibroelastic area.
	*Classification of '''residual cancer''', for which there are multiple systems, mainly ''Residual Cancer Burden'' (RCB)<ref group=notes>A calculator and explanations for calculating RCB is found at: http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3</ref> and the American Joint Committee on Cancer post-neoadjuvant therapy staging system (yAJCC).<ref name="pmid28577078">{{cite journal\| author=Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A \| display-authors=etal\| title=Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). \| journal=Breast Cancer Res Treat \| year= 2017 \| volume= 165 \| issue= 1 \| pages= 181-191 \| pmid=28577078 \| doi=10.1007/s10549-017-4303-8 \| pmc=5653207 \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28577078 }} </ref>		*Classification of '''residual cancer''', for which there are multiple systems, mainly ''Residual Cancer Burden'' (RCB)<ref group=notes>A calculator and explanations for calculating RCB is found at: http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3</ref> and the American Joint Committee on Cancer post-neoadjuvant therapy staging system (yAJCC).<ref name="pmid28577078">{{cite journal\| author=Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A \| display-authors=etal\| title=Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). \| journal=Breast Cancer Res Treat \| year= 2017 \| volume= 165 \| issue= 1 \| pages= 181-191 \| pmid=28577078 \| doi=10.1007/s10549-017-4303-8 \| pmc=5653207 \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28577078 }} </ref><noinclude>
			{{Bottom}}
			</noinclude>

Mikael Häggström: Started

2021-09-17T15:18:41Z

Started

New page

In neoadjuvant cases, measure:
*'''Tumor bed''' which generally manifests as a fibroelastic area.
*Classification of '''residual cancer''', for which there are multiple systems, mainly ''Residual Cancer Burden'' (RCB)<ref group=notes>A calculator and explanations for calculating RCB is found at: http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3</ref> and the American Joint Committee on Cancer post-neoadjuvant therapy staging system (yAJCC).<ref name="pmid28577078">{{cite journal| author=Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A | display-authors=etal| title=Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). | journal=Breast Cancer Res Treat | year= 2017 | volume= 165 | issue= 1 | pages= 181-191 | pmid=28577078 | doi=10.1007/s10549-017-4303-8 | pmc=5653207 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28577078 }} </ref>